Skip to main content
. 2023 Feb 28;4(1):102–138. doi: 10.37349/etat.2023.00125

Figure 1.

Figure 1.

The timeline of liquid biopsy development. The figure illustrates some of the significant events in the development and spread of the liquid biopsy in clinical practice. * Some of the Food and Drug Administration (FDA) approved tests, addressed in the following text of the manuscript (“ctDNA liquid biopsy assays” and “Clinical applications of ctDNA liquid biopsy”); NGS: next generation sequencing; MRD: minimal residual disease